scholarly journals Efficacy and safety of AAV2 gene therapy in children with aromatic L-amino acid decarboxylase deficiency: an open-label, phase 1/2 trial

2017 ◽  
Vol 1 (4) ◽  
pp. 265-273 ◽  
Author(s):  
Yin-Hsiu Chien ◽  
Ni-Chung Lee ◽  
Sheng-Hong Tseng ◽  
Chun-Hwei Tai ◽  
Shin-ichi Muramatsu ◽  
...  
2019 ◽  
Vol 85 (5) ◽  
pp. 644-652 ◽  
Author(s):  
Chih‐Hsien Tseng ◽  
Yin‐Hsiu Chien ◽  
Ni‐Chung Lee ◽  
Yung‐Chin Hsu ◽  
Shinn‐Forng Peng ◽  
...  

2012 ◽  
Vol 4 (134) ◽  
pp. 134ra61-134ra61 ◽  
Author(s):  
W.-L. Hwu ◽  
S.-i. Muramatsu ◽  
S.-H. Tseng ◽  
K.-Y. Tzen ◽  
N.-C. Lee ◽  
...  

Brain ◽  
2019 ◽  
Vol 142 (2) ◽  
pp. 322-333 ◽  
Author(s):  
Karin Kojima ◽  
Takeshi Nakajima ◽  
Naoyuki Taga ◽  
Akihiko Miyauchi ◽  
Mitsuhiro Kato ◽  
...  

Author(s):  
Francesca Marchese ◽  
Elena Faedo ◽  
Maria Stella Vari ◽  
Patrizia Bergonzini ◽  
Michele Iacomino ◽  
...  

AbstractAromatic L-amino acid decarboxylase (AADC) deficiency is an autosomal recessive metabolic disorder resulting from disease-causing pathogenic variants of the dopa decarboxylase (DDC) gene. The neurological features of AADC deficiency include early-onset hypotonia, oculogyric crises, ptosis, dystonia, hypokinesia, impaired development, and autonomic dysfunction. We report a patient with genetically confirmed AADC deficiency presenting with developmental epileptic encephalopathy (DEE). We report a boy with severe intractable epileptic spasms and DEE. The patient was evaluated for cognitive and neurologic impairment. Exome sequencing revealed a homozygous mutation (NM_000790.4:c.121C > A; p.Leu41Met) in the DDC gene. This case expands the clinical spectrum of AADC deficiency and strengthens the association between dopa decarboxylase deficiency and epilepsy. Additional studies are warranted to clarify the mechanisms linking dopa decarboxylase dysfunction to DEE.


Sign in / Sign up

Export Citation Format

Share Document